Jack Shuang Hou: Novo Nordisk to Present New Haemophilia Data on Investigational Denecimig at ISTH 2026
Jack Shuang Hou, Diagnostic Executive, Microfluidics and Immunoassay Specialist, shared a post on LinkedIn:
“Novo Nordisk to Present New Haemophilia Data at ISTH 2026 Highlighting Investigational Denecimig (Mim8)
Novo Nordisk will present new clinical and real-world data across its haemophilia portfolio at the ISTH 2026 Congress, featuring multiple analyses of investigational denecimig (Mim8) and new pediatric data for Alhemo (concizumab).
The presentations reinforce Novo Nordisk’s long-standing commitment to advancing innovation in rare bleeding disorders.
1.Denecimig (Mim8) Highlights
Phase 3 FRONTIER4 long-term data
- Adults, adolescents and children
- Patients with or without FVIII inhibitors
- Once-monthly, every-2-week and weekly prophylaxis evaluated
- Long-term efficacy, safety and patient-reported outcomes
2.Alhemo (Concizumab)
First Phase 3 explorer10 pediatric data
- Children younger than 11 years with haemophilia A or B and inhibitors
- Efficacy, safety and PK and PD results
- Pediatric indication remains investigational
3.Looking Ahead
Novo Nordisk will also present real-world evidence, physician preference studies and mechanistic research while continuing regulatory review of denecimig, following its U.S. BLA submission in 2025.
Leadership Perspective
Martin Holst Lange, Chief Scientific Officer at Novo Nordisk, said the company’s research reflects decades of listening to the haemophilia community while advancing person-centered innovation to improve care.
My takeaway
Novo Nordisk continues to build one of the industry’s most comprehensive haemophilia portfolios. With flexible prophylactic dosing, expanding pediatric evidence, and next-generation bispecific antibodies like denecimig, the company is positioning itself to further reshape long-term management across the full spectrum of haemophilia A.”
Stay updated with Hemostasis Today.
-
Sep 28, 2026, 03:59Rahul Saha: JAMA The 49th Human Blood Group System
-
Sep 28, 2026, 01:51Ann Mullally: Expect to See Lots More Gene Therapy in Medicine in the Years Ahead
-
Sep 27, 2026, 15:49Rana Al-Hrout: Iron Deficency – Is Ferritin 15ng/mL or Less Still the Cutoff?
-
Sep 27, 2026, 15:49Ayushi Sharma: What I Thought Transfusion Medicine Would Be vs What It Actually Is
-
Sep 27, 2026, 15:48William Wallace: How Much Human Research Is Behind the Supplements We Take?
-
Sep 27, 2026, 15:46Franck Perraudin: Lp(a) Lowering Alone May Not Be Enough
-
Sep 27, 2026, 15:41Ahmed Hamandi: Sharing Real-World HSCT Experience at the Iraqi Society of Haematology Conference
-
Sep 27, 2026, 15:39Co-creating Digital Support With Young Stroke Survivors – European Stroke Organisation
-
Sep 27, 2026, 15:39Eleri Schiavone: Celebrating 80 Years of the Welsh Blood Service